Medindia LOGIN REGISTER
Medindia
Advertisement

New ACC/AHA Guidelines for Lipids for People With Diabetes Questioned

by Kathy Jones on June 14, 2014 at 5:21 PM
 New ACC/AHA Guidelines for Lipids for People With Diabetes Questioned

Two researchers will debate whether guidelines for the treatment of high cholesterol are appropriate or not for people with type 2 diabetes at a symposium to be held on Tuesday, June 17, at the American Diabetes Association's 74th Scientific Sessions®.

At issue are the newest guidelines issued jointly by the American College of Cardiology and American Heart Association in November 2013. Previous guidelines for treating people with high cholesterol were based upon cutpoints for low-density lipoprotein (LDL) cholesterol levels (the so-called "bad" cholesterol). People whose cholesterol levels hit those cutpoints were asked to initiate dietary changes, and, if that failed to lower levels sufficiently, statin therapy was recommended.

Advertisement

The new guidelines divide patients into four groups for whom statin treatment is recommended: individuals with cardiovascular disease; individuals with LDL cholesterol (LDL-C) levels higher than 190 mg/dL; individuals with diabetes, between the ages of 40-75, with LDL-C levels 70-189 mg/dL; and individuals without diabetes or cardiovascular disease, with LDL-C 70-189 mg/dL, and an estimated risk of cardiovascular disease greater than 7.5 percent. There are no specific target levels for lowering cholesterol, only the recommendation that statins be used to reduce it.

Under the new guidelines, the vast majority of people with type 2 diabetes would be recommended for statin therapy. But is that the right call?

Robert H. Eckel, MD, Professor of Medicine and Charles A. Boettcher Chair in Atherosclerosis at the University of Colorado, Anschutz Medical Campus, says, "Yes. Almost all people with diabetes should be on a statin. That's what the evidence tells us. You may not like the new guidelines, but these are evidence-based and this is what the evidence says."
Advertisement

Henry Ginsberg, MD, Irving Professor of Medicine and Director of the Irving Institute for Clinical and Translational Research at Columbia University, disagrees. "The guideline committee used the evidence-based construct much too narrowly," he said.

Ginsberg explained that he agreed with the recommendation to examine a person's risk for cardiovascular disease as well as their cholesterol level when determining whether to prescribe a statin. But he did not agree with the removal of target LDL cholesterol goals once a person is being treated with medication, or with the lack of recommendations for additional or alternative therapies.

"There are people who can't take a high dose of a statin, or who won't respond as well to a high dose," he said. "In that case, you should be adding another medication. The new guidelines try to make it too simple."

Ginsberg said the new guidelines actually ignore evidence that shows the lower a patient's LDL-C level, the better. "How do you get to those lower levels if statins alone aren't enough?" he asked. "You add a non-statin."

But Eckel said that exceptions, which often come up in patients with diabetes, are addressed in the new guidelines by suggesting that physicians make a judgment call. "It should be an educated judgment, though, based on an understanding of the increased risk of heart disease and stroke for people with diabetes."

The American Diabetes Association recommends that people with diabetes keep LDL-C levels at or below 100 mg/dL, or under 70 mg/dL if they also have cardiovascular disease. The Association recommends using high-dose statin therapy to reach those goals.

Ginsberg said he agrees with the Association's present guidelines, noting that they are based on a wealth of data that includes, but is not restricted to, randomized clinical trials.
Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cholesterol News

High and Low HDL Cholesterol Levels Linked to Higher Dementia Risk
In the elderly population, both high and low levels of high-density lipoprotein (HDL) cholesterol, are linked to a slight increase in the risk of dementia.
World First Drug to Address Deadly 'Bad Cholesterol'
Muvalaplin, an oral drug, offers the path-breaking world's first treatment for lipoprotein(a), a bad cholesterol that increases the risk of heart attack and stroke.
Are Heart Attack Survivors Neglecting LDL Cholesterol Risk?
Low-density lipoprotein cholesterol (LDL cholesterol) plays a significant role in elevating the likelihood of heart attacks and strokes.
Cholesterol Testing System Developed
New technology for identifying cholesterol levels that is cheaper, more efficient, and faster than traditional analogues developed.
 High Cholesterol Has Tender Spot In Heart Disease
New research questions the efficacy of statins prescribed to lower cholesterol levels in patients with heart disease.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New ACC/AHA Guidelines for Lipids for People With Diabetes Questioned Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests